about
Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary historyInferring haplotypes at the NAT2 locus: the computational approach.Evaluating NAT2PRED for inferring the individual acetylation status from unphased genotype dataAn integrative approach to identifying cancer chemoresistance-associated pathwaysGenetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate.Variation in NAT2 acetylation phenotypes is associated with differences in food-producing subsistence modes and ecoregions in Africa.Interspecies differences in pharmacokinetics and metabolism of S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethylphenyl)-propionamide: the role of N-acetyltransferase.Improving pharmacotherapy outcomes by pharmacogenomics: from expectation to reality?Redox regulation of the human xenobiotic metabolizing enzyme arylamine N-acetyltransferase 1 (NAT1). Reversible inactivation by hydrogen peroxide.Peroxynitrite irreversibly inactivates the human xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 (NAT1) in human breast cancer cells: a cellular and mechanistic study.AcetylationSNP selection at the NAT2 locus for an accurate prediction of the acetylation phenotype.Skeletal muscles express the xenobiotic-metabolizing enzyme arylamine N-acetyltransferase.NAT2 Gene Polymorphisms in Turkish Patients with Psoriasis Vulgaris.Comparison ofN-Acetyltransferase-2 Enzyme Genotype-Phenotype and Xanthine Oxidase Enzyme Activity Between Swedes and KoreansN-acetyltransferase-2 (NAT2) Gene Polymorphisms and Enzyme Activity in Serbs: Unprecedented High Prevalence of Rapid Acetylators in a White Population
P2860
Q21283781-957E3872-5643-4C8D-9E7B-DE0247845870Q24815593-BD2ED4A2-3E56-4673-9EA4-0F6F5C6000DEQ33521506-09C61ECA-E876-4BCD-9F8B-36A729EE9605Q33853380-63C66AEA-88AA-4212-B02E-D575EEDFA27DQ35049590-F83AE7B6-4B50-4AF2-85AE-9752BC74FB42Q35856283-B383A1B1-1541-4262-9CC7-92409B766D36Q36087736-4AF7861A-15AD-4DA3-B741-EF79D7565D30Q36278015-1B4433AE-9E97-4425-B3AF-FAA1D6F9DEC3Q44495336-065661A3-8EDD-495E-B176-619A1F22FFC4Q44691529-E50B6F59-BD93-4A0B-8BD7-0FA0A42D88FDQ45317509-64BA8B97-70CE-4157-BD5B-576286AC679CQ51950592-5BC678F7-3BD5-4173-8DED-DE6D9946B95EQ54772782-5A441A9B-347F-498A-9F06-29B23DAC7867Q55501446-BB7514F2-50ED-4EC0-9C65-AD7B773D3E64Q58003090-3C1328B6-2DED-4549-B6CB-C56A085A582DQ58003100-55E06BC7-CEBA-4C44-AFEC-CA3C558B5558
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Arylamine N-acetyltransferases and drug response.
@ast
Arylamine N-acetyltransferases and drug response.
@en
Arylamine N-acetyltransferases and drug response.
@nl
type
label
Arylamine N-acetyltransferases and drug response.
@ast
Arylamine N-acetyltransferases and drug response.
@en
Arylamine N-acetyltransferases and drug response.
@nl
prefLabel
Arylamine N-acetyltransferases and drug response.
@ast
Arylamine N-acetyltransferases and drug response.
@en
Arylamine N-acetyltransferases and drug response.
@nl
P2860
P356
P1433
P1476
Arylamine N-acetyltransferases and drug response.
@en
P2093
Peter Meisel
P2860
P304
P356
10.1517/14622416.3.3.349
P577
2002-05-01T00:00:00Z